Granted Patent B2

US 12,485,135 · App. 18/516,416 · Granted Dec 2, 2025

Inventors: Karl D. Normington (Prides Crossing, MA); David A. Sinclair (Chestnut Hill, MA); David J. Livingston (Worcester, MA); James M. McKearin (Worcester, MA); Bruce Szczepankiewicz (Worcester, MA); Jonathan N. Kremsky (Worcester, MA)

Assignee: Metro International Biotech, LLC

A61K31/706A61K31/443A61K31/661A61K31/665C07F9/06C07F9/547C07F9/65586C07F9/6561C07F9/65742C07H11/04C07H19/048A61K31/7052C07H19/04

Abstract

Claims (49)

1 . A composition comprising a compound of formula I:

or a pharmaceutically acceptable salt thereof, wherein V is selected from hydrogen, phenyl and monocyclic heteroaryl, wherein (i) each said monocyclic heteroaryl contains five or six ring atoms of which 1 or 2 ring atoms are heteroatoms selected from N, S, and O, and the remainder of the ring atoms are carbon, and (ii) each said phenyl or monocyclic heteroaryl is unsubstituted or is substituted by one or two groups selected from halogen, trifluoromethyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, and cyano;

and a pharmaceutically acceptable carrier, diluent, stabilizer or excipient.

2 . A composition comprising a compound of formula II:

or a pharmaceutically acceptable salt thereof, wherein:

(a) R 1 is hydrogen; n-alkyl; branched alkyl; cycloalkyl; or aryl, where aryl is optionally substituted with at least one of C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, F, Cl, Br, I, nitro, cyano, C 1-6 haloalkyl, —N(R 1′ ) 2 , C 1-6 acylamino, —NHSO 2 C 1-6 alkyl, —SO 2 N(R 1′ ) 2 , COR 1″ , and —SO 2 C 1-6 alkyl;

R 1′ is independently hydrogen or alkyl selected from C 1-20 alkyl, C 1-10 alkyl, or C 1-6 alkyl, and

R 1″ is —OR′ or —N(R 1′ ) 2 ;

(b) R 2 is hydrogen, C 1-10 alkyl; or C(O)CR 3a R 3b NHR 1 , where n is 2 to 4; or

R 3a or R 3b and R 2 together are (CH 2 ) n forming a cyclic ring that includes the adjoining N and C atoms;

(c) R 3a and R 3b are:

(i) independently selected from hydrogen, C 1-10 alkyl, cycloalkyl, —(CH 2 ) c (NR 3′ ) 2 , C 1-6 hydroxyalkyl, —CH 2 SH, —(CH 2 ) 2 S(O) d Me, —(CH 2 ) 3 NHC(═NH)NH 2 , (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, —(CH 2 ) e COR 3″ , aryl and aryl C 1-3 alkyl, said aryl groups are optionally substituted with a group selected from hydroxyl, C 1-10 alkyl, C 1-6 alkoxy, halogen, nitro and cyano; or

(ii) R 3a and R 3b both are C 1-6 alkyl; or

(iii) R 3a and R 3b together are (CH 2 ) f so as to form a spiro ring; or

(iv) R 3a is hydrogen and R 3b and R 2 together are (CH 2 ) n forming a ring that includes the adjoining N and C atoms; or

(v) R 3b is hydrogen and R 3a and R 2 together are (CH 2 ) n forming a ring that includes the adjoining N and C atoms; or

(vi) R 3a is H and R 3b is H, CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH(CH 3 ) 2 , CH(CH 3 )CH 2 CH 3 , CH 2 Ph, CH 2 -indol-3-yl, CH 2 CH 2 SCH 3 , CH 2 CO 2 H, CH 2 C(O)NH 2 , CH 2 CH 2 COOH, CH 2 CH 2 C(O)NH 2 , CH 2 CH 2 CH 2 CH 2 NH 2 , CH 2 CH 2 CH 2 NHC(NH)NH 2 , CH 2 -imidazol-4-yl, CH 2 OH, CH(OH)CH 3 , CH 2 ((4′-OH)-Ph), CH 2 SH, or lower cycloalkyl; or

(vii) R 3a is CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH(CH 3 ) 2 , CH(CH 3 )CH 2 CH 3 , CH 2 Ph, CH 2 -indol-3-yl, —CH 2 CH 2 SCH 3 , CH 2 CO 2 H, CH 2 C(O)NH 2 , CH 2 CH 2 COOH, CH 2 CH 2 C(O)NH 2 , CH 2 CH 2 CH 2 CH 2 NH 2 , CH 2 CH 2 CH 2 NHC(NH)NH 2 , CH 2 -imidazol-4-yl, CH 2 OH, CH(OH)CH 3 , CH 2 ((4′-OH)-Ph), CH 2 SH, or lower cycloalkyl and R 3b is H;

c is from 1 to 6,

d is from 0 to 2,

e is from 0 to 3,

f is from 2 to 5,

n is from 2 to 4; and

(d) R 4 is hydrogen; C 1-10 alkyl optionally substituted with lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen; C 1-10 haloalkyl; C 3-10 cycloalkyl; cycloalkyl alkyl; cycloheteroalkyl; aminoacyl; aryl; heteroaryl; substituted aryl; or substituted heteroaryl; and a pharmaceutically acceptable carrier, diluent,

stabilizer or excipient.

3 . A composition comprising a compound of formula III:

or a pharmaceutically acceptable salt thereof, wherein W 1 and W 2 are each independently O − or OR 5 , and R 5 is hydrogen or alkyl; provided that when W 1 is O − , and W 2 is OR 5′ then R 5 is not hydrogen, methyl or butyl;

and a pharmaceutically acceptable carrier, diluent, stabilizer or excipient.

4 . A method of treating a disease or disorder associated with NAD+ biosynthesis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound of formula III:

or a pharmaceutically acceptable salt thereof, wherein W 1 and W 2 are each independently O − or OR 5 , and R 5 is hydrogen or alkyl; provided that when W 1 is O − , and W 2 is OR 5 then R 5 is not hydrogen, methyl or butyl.

5 . A method of treating a neurodegenerative disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the composition of claim 1 .

6 . A method of treating a neurodegenerative disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the composition of claim 2 .

7 . A method of treating a neurodegenerative disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound of formula III:

or a pharmaceutically acceptable salt thereof, wherein W 1 and W 2 are each independently O − or OR 5 , and R 5 is hydrogen or alkyl; provided that when W 1 is O − , and W 2 is OR 5 then R 5 is not hydrogen, methyl or butyl.

8 . A method of regulating abnormal blood glucose concentration in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the composition of claim 1 .

9 . A method of regulating abnormal blood glucose concentration in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the composition of claim 2 .

10 . A method of regulating abnormal blood glucose concentration in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound of formula III:

or a pharmaceutically acceptable salt thereof, wherein W 1 and W 2 are each independently O − or OR 5 , and R 5 is hydrogen or alkyl; provided that when W 1 is O − , and W 2 is OR 5′ then R 5 is not hydrogen, methyl or butyl.

11 . A method of making the compound of formula III:

wherein W 1 and W 2 are each independently O − or OR 5 , and R 5 is hydrogen or alkyl; provided that when W 1 is O − , and W 2 is OR 5′ then R 5 is not hydrogen, methyl or butyl;

the method comprising:

reacting a compound having the structure:

with a compound having the structure:

in the presence of tetrazole and acetonitrile to afford compound (iii):

and converting compound (iii) to the compound of formula III.

12 . A method of preparing a crystalline solid form of the compound of formula III:

wherein W 1 and W 2 are each independently O − or OR 5 , and R 5 is hydrogen or alkyl; provided that when W 1 is O − , and W 2 is OR 5′ then R 5 is not hydrogen, methyl or butyl; wherein the method comprises:

a) dissolving the compound of formula III in a solvent to form a solution; and

b) crystallizing the compound of formula III from the solution to form the crystalline solid, wherein the solvent comprises ethyl acetate and methanol.

Assignments (2)

Continuity (7)

References Cited (395)